/PRNewswire/ -- IndyGeneUS Bio 今天宣布提交了一项专利申请，涵盖其 Clinico-Genomic Insight Engine™ (CGIE™)——一个正在开发的基础平台，旨在支持受监管的全基因组分析、人工智能驱动的靶点发现以及用于制药和公共部门的安全基因数据操作。
该专利申请由 Wilson Sonsini Goodrich &amp; Rosati 提交，这是一家广受认可的律师事务所，专门代表处于创新前沿的风险投资支持的科技和生命科学公司。
继续阅读
<img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/>
IndyGeneUS Bio
此项申请的提交正值药物开发者、投资者和监管机构日益重视可扩展的基因组基础设施之际，该基础设施能够支持人工智能驱动的发现，同时满足安全性、合规性和数据治理的严格要求。随着开发成本上升和生物复杂性仍未得到充分探索，整合基因组学、人工智能和受监管计算的平台正在成为下一代治疗的关键推动者。
巴尔的摩发展公司 是这家由退伍军人领导的黑人拥有公司的主要种子投资者，进一步巩固了巴尔的摩作为国家先进生命科学基础设施、人工智能和数据驱动生物医学创新中心的日益重要角色。
&#34;CGIE™ 被构建为面向未来的基础设施，而不是一个点解决方案，&#34; IndyGeneUS Bio 的创始人兼首席执行官 Yusuf Henriques 说。&#34;我们的目标是建立 AI×Bio Factory——基因组学的黑石集团——能够将人口规模的基因组数据转化为持久的生物医学和治疗资产。&#34;
IndyGeneUS Bio 的 AI×Bio Factory 的核心引擎是 CGIE™，它将安全的全基因组测序工作流程、高性能计算和审计准备的数据治理整合到一个统一的平台中。该系统正在开发中，以支持受监管的基因组工作负载，包括变异发现、人工智能模型训练和纵向分析，初步部署预计在 2026 年进行。
根据公司说法，AI×Bio Factory 架构与美国国家安全委员会在新兴生物技术方面阐述的国家优先事项相一致，该委员会已将生物技术、人工智能和安全数据基础设施确定为美国竞争力、韧性和健康安全的战略资产。
&#34;与许多主要依赖西方来源基因组数据集的人工智能驱动药物发现平台不同，CGIE™ 旨在通过整合来自非洲侨民和土著人群的数据来扩展基因组参考空间，&#34; Henriques 说。&#34;这些群体代表了人类基因多样性的最高水平，并在现有数据库中显著缺乏代表性。&#34;
Henriques 是前美国陆军战斗医护人员和前 FDA 监管者，得到了来自 霍华德大学 的多学科创始团队的支持，Henriques 目前正在攻读跨学科生物医学科学 (IBMS) 的博士学位。
最近，IndyGeneUS Bio 与一家大型合同研究组织 (CRO) 在非洲签署了独家商业化协议，以验证超过 500,000 份全血样本。这些样本将在整合到 CGIE™ 平台之前，经过严格的质量验证，包括活力评估和全基因组测序准备。
BDC 和 DownEast Digital 联合体的种子资金正在用于完成 CGIE™ 平台开发，并推进与制药和公共部门合作伙伴的早期 AI×Bio Factory 试点项目。公司预计将在 2026 年期间围绕平台验证和规模扩大里程碑与潜在的合作伙伴和投资者进行接洽。
媒体联系人： Angel Livas
3016743253
[email protected]
来源 IndyGeneUS Bio
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTEyJk5ld3NJdGVtSWQ9UEg2MTAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTIwOTQ1UFJfTkVXU19VU1BSX19fX19QSDYxMDE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTEyJk5ld3NJdGVtSWQ9UEg2MTAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTIwOTQ1UFJfTkVXU19VU1BSX19fX19QSDYxMDE5"/>

IndyGeneUS Bio 已申请其临床基因组洞察引擎™（Clinico-Genomic Insight Engine™，CGIE™）的专利，旨在支持受监管的全基因组分析和基于人工智能的靶点发现。该平台整合了制药和公共部门使用的基因组数据操作，满足可扩展基因组基础设施的需求。该公司获得了巴尔的摩发展公司的支持，旨在将基因组数据转化为生物医学资产。CGIE™ 将整合来自非洲人群的多样化基因组数据，并计划于 2026 年首次部署。资金将用于推进开发和与合作伙伴的试点项目

, /PRNewswire/ -- IndyGeneUS Bio today announced the filing of a patent application covering its Clinico-Genomic Insight Engine™ (CGIE™)—a foundational platform under development to support regulated whole-genome analysis, AI-enabled target discovery, and secure genomic data operations for pharmaceutical and public-sector use.
<div class="lb-trans">/PRNewswire/ -- IndyGeneUS Bio 今天宣布提交了一项专利申请，涵盖其 Clinico-Genomic Insight Engine™ (CGIE™)——一个正在开发的基础平台，旨在支持受监管的全基因组分析、人工智能驱动的靶点发现以及用于制药和公共部门的安全基因数据操作。
</div>The patent application was filed by Wilson Sonsini Goodrich &amp; Rosati, a law firm widely recognized for representing venture-backed technology and life-science companies at the forefront of innovation.
<div class="lb-trans">该专利申请由 Wilson Sonsini Goodrich &amp; Rosati 提交，这是一家广受认可的律师事务所，专门代表处于创新前沿的风险投资支持的科技和生命科学公司。
</div>Continue Reading
<div class="lb-trans">继续阅读
</div><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/>
IndyGeneUS Bio
<div class="lb-trans">IndyGeneUS Bio
</div>The filing comes at a time when drug developers, investors, and regulators are increasingly prioritizing scalable genomic infrastructure capable of supporting AI-driven discovery while meeting stringent requirements for security, compliance, and data governance. As development costs rise and biological complexity remains underexplored, platforms that integrate genomics, artificial intelligence, and regulated compute are emerging as critical enablers of next-generation therapeutics.
<div class="lb-trans">此项申请的提交正值药物开发者、投资者和监管机构日益重视可扩展的基因组基础设施之际，该基础设施能够支持人工智能驱动的发现，同时满足安全性、合规性和数据治理的严格要求。随着开发成本上升和生物复杂性仍未得到充分探索，整合基因组学、人工智能和受监管计算的平台正在成为下一代治疗的关键推动者。
</div>Baltimore Development Corporation is the lead seed investor in the veteran-led and black-owned company, reinforcing Baltimore's growing role as a national hub for advanced life-science infrastructure, artificial intelligence, and data-driven biomedical innovation.
<div class="lb-trans">巴尔的摩发展公司 是这家由退伍军人领导的黑人拥有公司的主要种子投资者，进一步巩固了巴尔的摩作为国家先进生命科学基础设施、人工智能和数据驱动生物医学创新中心的日益重要角色。
</div>&#34;CGIE™ is being built as future-facing infrastructure rather than a point solution,&#34; said Yusuf Henriques, Founder and CEO of IndyGeneUS Bio. &#34;Our objective is to establish the AI×Bio Factory—the BlackRock of Genomics—capable of transforming population-scale genomic data into durable biomedical and therapeutic assets.&#34;
<div class="lb-trans">&#34;CGIE™ 被构建为面向未来的基础设施，而不是一个点解决方案，&#34; IndyGeneUS Bio 的创始人兼首席执行官 Yusuf Henriques 说。&#34;我们的目标是建立 AI×Bio Factory——基因组学的黑石集团——能够将人口规模的基因组数据转化为持久的生物医学和治疗资产。&#34;
</div>The core engine of IndyGeneUS Bio's AI×Bio Factory is CGIE™, which integrates secure whole-genome sequencing workflows, high-performance computing, and audit-ready data governance into a unified platform. The system is being developed to support regulated genomic workloads, including variant discovery, AI model training, and longitudinal analysis, with initial deployments anticipated in 2026.
<div class="lb-trans">IndyGeneUS Bio 的 AI×Bio Factory 的核心引擎是 CGIE™，它将安全的全基因组测序工作流程、高性能计算和审计准备的数据治理整合到一个统一的平台中。该系统正在开发中，以支持受监管的基因组工作负载，包括变异发现、人工智能模型训练和纵向分析，初步部署预计在 2026 年进行。
</div>According to the company, the AI×Bio Factory architecture aligns with national priorities articulated by the U.S. National Security Commission on Emerging Biotechnology, which has identified biotechnology, artificial intelligence, and secure data infrastructure as strategic assets for U.S. competitiveness, resilience, and health security.
<div class="lb-trans">根据公司说法，AI×Bio Factory 架构与美国国家安全委员会在新兴生物技术方面阐述的国家优先事项相一致，该委员会已将生物技术、人工智能和安全数据基础设施确定为美国竞争力、韧性和健康安全的战略资产。
</div>&#34;Unlike many AI-enabled drug-discovery platforms that rely primarily on Western-derived genomic datasets, CGIE™ is designed to expand genomic reference space by incorporating data from African diaspora and Indigenous populations,&#34; says Henriques. &#34;These groups represent the highest levels of human genetic diversity and remain significantly underrepresented in existing databases.&#34;
<div class="lb-trans">&#34;与许多主要依赖西方来源基因组数据集的人工智能驱动药物发现平台不同，CGIE™ 旨在通过整合来自非洲侨民和土著人群的数据来扩展基因组参考空间，&#34; Henriques 说。&#34;这些群体代表了人类基因多样性的最高水平，并在现有数据库中显著缺乏代表性。&#34;
</div>Henriques, a former U.S. Army combat medic and former FDA regulator is supported by a multidisciplinary founding team of fellow Howard University alumni where Henriques is currently pursuing a PhD in Interdisciplinary Biomedical Sciences (IBMS).
<div class="lb-trans">Henriques 是前美国陆军战斗医护人员和前 FDA 监管者，得到了来自 霍华德大学 的多学科创始团队的支持，Henriques 目前正在攻读跨学科生物医学科学 (IBMS) 的博士学位。
</div>Recently, IndyGeneUS Bio entered into an exclusive commercialization agreement with a large contract research organization (CRO) in Africa to validate more than 500,000 whole-blood samples. These samples will undergo rigorous quality verification, including viability assessment and whole-genome sequencing readiness, prior to integration into the CGIE™ platform.
<div class="lb-trans">最近，IndyGeneUS Bio 与一家大型合同研究组织 (CRO) 在非洲签署了独家商业化协议，以验证超过 500,000 份全血样本。这些样本将在整合到 CGIE™ 平台之前，经过严格的质量验证，包括活力评估和全基因组测序准备。
</div>Deployment of seed funding by BDC and DownEast Digital syndicate are being utilized to complete CGIE™ platform development and advance early AI×Bio Factory pilot programs with pharmaceutical and public-sector partners. The company expects to engage prospective collaborators and investors around platform validation and scale-up milestones throughout 2026.
<div class="lb-trans">BDC 和 DownEast Digital 联合体的种子资金正在用于完成 CGIE™ 平台开发，并推进与制药和公共部门合作伙伴的早期 AI×Bio Factory 试点项目。公司预计将在 2026 年期间围绕平台验证和规模扩大里程碑与潜在的合作伙伴和投资者进行接洽。
</div>Media Contact: Angel Livas
<div class="lb-trans">媒体联系人： Angel Livas
</div>3016743253
<div class="lb-trans">3016743253
</div>[email protected]
<div class="lb-trans">[email protected]
</div>SOURCE IndyGeneUS Bio
<div class="lb-trans">来源 IndyGeneUS Bio
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTEyJk5ld3NJdGVtSWQ9UEg2MTAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTIwOTQ1UFJfTkVXU19VU1BSX19fX19QSDYxMDE5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH61019&amp;Transmission_Id=202601120945PR_NEWS_USPR_____PH61019&amp;DateId=20260112"/>

IndyGeneUS Bio 为 Clinico-Genomic Insight Engine™申请专利，推动其 AI×Bio Factory Hub 从巴尔的摩扩展至非洲